Levomilnacipran

From Self-sufficiency
Jump to: navigation, search
Levomilnacipran
File:Levomilnacipran.png
Systematic (IUPAC) name
(1R,2S)-2-(aminomethyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide
Clinical data
Routes of
administration		 Oral
Legal status
Legal status
  • Uncontrolled
Identifiers
CAS Number 96847-55-1
ATC code none
PubChem CID 65833
Chemical data
Formula C15H22N2O
Molar mass 246.348 g/mol[[Script error: No such module "String".]]
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Levomilnacipran (F2695) is an antidepressant currently under development by Forest Laboratories for the treatment of depression in the United States and Canada.[1][2][3] As of 2009 it is in phase III clinical trials.[4] Levomilnacipran is an active enantiomer of milnacipran and therefore has similar effects and pharmacology, acting as a serotonin-norepinephrine reuptake inhibitor.[2][5]

See also

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />
GABAA PAMs
Others
α2δ VDCC Blockers
5-HT1A Agonists
Azapirones: Buspirone • Gepirone • Tandospirone; Others: Flesinoxan • Oxaflozane
H1 Antagonists
Diphenylmethanes: Captodiame • Hydroxyzine; Others: Brompheniramine • Chlorpheniramine • Pheniramine
CRH1 Antagonists
NK2 Antagonists
MCH1 antagonists
mGluR2/3 Agonists
mGluR5 NAMs
TSPO agonists
σ1 agonists
Others

M: PSO/PSI

dsrd (o, p, m, p, a, d, s), sysi/epon, spvo

proc, drug(N5A/5B/5C/6A/6B/6D)

35px This drug article relating to the nervous system is a stub. You can help ssf by expanding it.
  1. ↑ "Future Treatments for Depression, Anxiety, Sleep Disorders, Psychosis, and ADHD -- Neurotransmitter.net". 
  2. ↑ 2.0 2.1 "Pierre Fabre Medicament and Forest Laboratories to Collaborate on Development and Commercialization of F2695 for Depression - FierceBiotech". 
  3. ↑ "Search of: F2695 - List Results - ClinicalTrials.gov". 
  4. ↑ Deprez D, Chassard D, Baille P, Mignot A, Ung HL, Puozzo C (1998). "Which bioequivalence study for a racemic drug? Application to milnacipran". European Journal of Drug Metabolism and Pharmacokinetics. 23 (2): 166–71. PMID 9725476. 
Retrieved from "http://ssf.f15ijp.com/wiki/index.php?title=Levomilnacipran&oldid=22802"